Cedars-Sinai Heart Institute, Los Angeles, California.
Medical University of Vienna, Vienna, Austria.
J Heart Lung Transplant. 2014 Apr;33(4):327-40. doi: 10.1016/j.healun.2014.02.027. Epub 2014 Mar 5.
Although primary graft dysfunction (PGD) is fairly common early after cardiac transplant, standardized schemes for diagnosis and treatment remain contentious. Most major cardiac transplant centers use different definitions and parameters of cardiac function. Thus, there is difficulty comparing published reports and no agreed protocol for management. A consensus conference was organized to better define, diagnose, and manage PGD. There were 71 participants (transplant cardiologists, surgeons, immunologists and pathologists), with vast clinical and published experience in PGD, representing 42 heart transplant centers worldwide. State-of-the-art PGD presentations occurred with subsequent breakout sessions planned in an attempt to reach consensus on various issues. Graft dysfunction will be classified into primary graft dysfunction (PGD) or secondary graft dysfunction where there is a discernible cause such as hyperacute rejection, pulmonary hypertension, or surgical complications. PGD must be diagnosed within 24 hours of completion of surgery. PGD is divided into PGD-left ventricle and PGD-right ventricle. PGD-left ventricle is categorized into mild, moderate, or severe grades depending on the level of cardiac function and the extent of inotrope and mechanical support required. Agreed risk factors for PGD include donor, recipient, and surgical procedural factors. Recommended management involves minimization of risk factors, gradual increase of inotropes, and use of mechanical circulatory support as needed. Retransplantation may be indicated if risk factors are minimal. With a standardized definition of PGD, there will be more consistent recognition of this phenomenon and treatment modalities will be more comparable. This should lead to better understanding of PGD and prevention/minimization of its adverse outcomes.
虽然原发性移植物功能障碍(PGD)在心脏移植后早期相当常见,但诊断和治疗的标准化方案仍存在争议。大多数主要的心脏移植中心使用不同的心脏功能定义和参数。因此,比较已发表的报告存在困难,也没有达成一致的管理方案。为此,组织了一次共识会议,以更好地定义、诊断和管理 PGD。有 71 名参与者(移植心脏病专家、外科医生、免疫学家和病理学家),他们在 PGD 方面具有广泛的临床和发表经验,代表了全球 42 个心脏移植中心。会上进行了有关 PGD 的最新演讲,随后计划了分组讨论会议,试图就各种问题达成共识。移植物功能障碍将分为原发性移植物功能障碍(PGD)或继发性移植物功能障碍,后者有明显的原因,如超急性排斥反应、肺动脉高压或手术并发症。PGD 必须在手术后 24 小时内诊断。PGD 分为左心室 PGD 和右心室 PGD。左心室 PGD 根据心脏功能水平和需要的正性肌力药和机械支持程度分为轻度、中度或重度。公认的 PGD 危险因素包括供体、受体和手术操作因素。推荐的管理方法包括最小化危险因素、逐渐增加正性肌力药,并根据需要使用机械循环支持。如果危险因素最小化,则可能需要重新移植。通过标准化的 PGD 定义,将更一致地认识到这种现象,治疗方式也将更具可比性。这应该会导致更好地理解 PGD,并预防/最小化其不良后果。